K Van Herck1, E Leuridan, P Van Damme. 1. Centre for the Evaluation of Vaccination, WHO Collaborating Centre for Prevention and Control of Viral Hepatitis, Department Epidemiology and Social Medicine, University of Antwerp, Campus Drie Eiken, Antwerp, Belgium. koen.vanherck@ua.ac.be
Abstract
INTRODUCTION: Vaccination is an important tool in hepatitis B prevention. However, several vaccine doses are required to induce long-term protection. Several at-risk groups have difficulties in adhering to the standard vaccination schedule. OBJECTIVES: This paper aims to review the use of accelerated hepatitis B vaccination schedules, in terms of immunogenicity and compliance. RESULTS: Accelerated schedules (0.1.2.12 months) or super-accelerated schedules (0.7.21.360 days) have been shown to result in higher proportions of healthy vaccinees reaching anti-HBs antibody levels >or=10 IU/l more rapidly. A fourth completing dose is required to lift antibody levels to an equal height, as does a standard (0.1.6 months) schedule. Accelerated schedules do also increase the uptake of hepatitis B vaccine, that is the proportion of vaccinees who receive three doses. However, completing the schedule with a fourth dose is usually more difficult than completing a standard 0.1.6-month schedule. Several additional tools can help to increase the compliance (eg, reminder systems, outreach services and incentive schemes). CONCLUSION: For rapid seroconversion and almost immediate protection in the short term, a (super)accelerated schedule could be used in at-risk groups. As long-term protection data with these (super) accelerated schedules have not been documented yet, a fourth dose at month 12 is still required. A shortened schedule (0.1.4 months) might be an alternative worth considering compared with the standard 0.1.6, as it convenes to internationally accepted minimum dose intervals and offers earlier protection. There is a clear need to study the long-term protection and effectiveness of the primary part of (super)accelerated schedules.
INTRODUCTION: Vaccination is an important tool in hepatitis B prevention. However, several vaccine doses are required to induce long-term protection. Several at-risk groups have difficulties in adhering to the standard vaccination schedule. OBJECTIVES: This paper aims to review the use of accelerated hepatitis B vaccination schedules, in terms of immunogenicity and compliance. RESULTS: Accelerated schedules (0.1.2.12 months) or super-accelerated schedules (0.7.21.360 days) have been shown to result in higher proportions of healthy vaccinees reaching anti-HBs antibody levels >or=10 IU/l more rapidly. A fourth completing dose is required to lift antibody levels to an equal height, as does a standard (0.1.6 months) schedule. Accelerated schedules do also increase the uptake of hepatitis B vaccine, that is the proportion of vaccinees who receive three doses. However, completing the schedule with a fourth dose is usually more difficult than completing a standard 0.1.6-month schedule. Several additional tools can help to increase the compliance (eg, reminder systems, outreach services and incentive schemes). CONCLUSION: For rapid seroconversion and almost immediate protection in the short term, a (super)accelerated schedule could be used in at-risk groups. As long-term protection data with these (super) accelerated schedules have not been documented yet, a fourth dose at month 12 is still required. A shortened schedule (0.1.4 months) might be an alternative worth considering compared with the standard 0.1.6, as it convenes to internationally accepted minimum dose intervals and offers earlier protection. There is a clear need to study the long-term protection and effectiveness of the primary part of (super)accelerated schedules.
Authors: B G Gellin; R N Greenberg; R H Hart; J S Bertino; D H Stein; M A Deloria; M L Clements-Mann Journal: J Infect Dis Date: 1997-06 Impact factor: 5.226
Authors: L S Marsano; R N Greenberg; R B Kirkpatrick; R K Zetterman; A Christiansen; D J Smith; M D DeMedina; E R Schiff Journal: Am J Gastroenterol Date: 1996-01 Impact factor: 10.864
Authors: Karen H Seal; Alex H Kral; Jennifer Lorvick; Alex McNees; Lauren Gee; Brian R Edlin Journal: Drug Alcohol Depend Date: 2003-08-20 Impact factor: 4.492
Authors: A E Brown; S E Tomkins; L E Logan; D S Lamontagne; H L Munro; V D Hope; A Righarts; J E Blackham; B D Rice; T R Chadborn; P A Tookey; J V Parry; V Delpech; O N Gill; K A Fenton Journal: Sex Transm Infect Date: 2006-02 Impact factor: 3.519
Authors: Maarten F Schim van der Loeff; Alex Vorsters; Elske Marra; Pierre Van Damme; Arjan Hogewoning Journal: Hum Vaccin Immunother Date: 2019-07-26 Impact factor: 3.452